First Australian COVID-19 DNA vaccine trial commences

Australian researchers commence the first Phase 1 human trial of a COVID-19 gene-based DNA vaccine in Australia, delivered via a needle-free system. Led by the University of Sydney, Scientia Clinical Research (Sydney), Telethon Kids Institute (Perth) and the Women’s and Children’s Hospital (Adelaide), the COVALIA trial uses a gene-based vaccine with DNA sequences from the SARS-CoV2 virus. The researchers have partnered with Australian biotech company Technovalia and its international vaccine partner BioNet who developed the DNA vaccine. It uses similar technology to other genetic vaccines, like mRNA, in use in Australia and internationally. Gene-based vaccines use genetic (DNA) sequences from the virus. Researchers identify and isolate parts (genes) of the virus genome. Once the DNA is inside the cell the body uses the DNA code to make the coronavirus spike protein trigger an immune response. This potential next-generation vaccine has no additives or preservatives. It will be given using a needle-free device that penetrates...